Press Release: Novartis: AveXis presents new data -2-

potentially contributed to the concurrent events of abnormal liver function tests (elevation of liver enzymes called transaminases), abnormal blood tests (low platelets) and low blood pressure. The serious adverse events (SAE) reports will be updated accordingly and submitted to the Health Authorities....
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Thursday, 19 September
Share |